Bristol-Myers Squibb

8 More Big Pharma Events in 2019 You Don't Want to Miss
Motley Fool
Mon, 07/22/19 - 09:44 am
Novartis
Pfizer
AbbVie
Bristol-Myers Squibb
Merck
GSK
Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study
Yahoo/Zacks.com
Sat, 07/20/19 - 08:25 pm
Bristol-Myers Squibb
Bayer
Ono Pharmaceutical
Opdivo
Stivarga
metastatic colorectal cancer
These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
Investors Business Daily
Fri, 07/19/19 - 10:44 am
Bristol-Myers Squibb
Celgene
M&A
Otezla
Gilead Sciences
Amgen
Regeneron
Eli Lilly
JNJ
Bayer, Bristol-Myers Squibb and Ono Pharma Team on Colorectal Cancer
BioSpace
Thu, 07/18/19 - 10:24 am
Bayer
Bristol-Myers Squibb
Ono Pharmaceutical
metastatic colorectal cancer
Why Bristol-Myers Squibb Stock Plunged in the First Half of 2019
Motley Fool
Mon, 07/8/19 - 10:23 pm
Bristol-Myers Squibb
Celgene
M&A
Pressing the pause button on CAR-T cells with Bristol-Myers’ leukemia drug
Fierce Biotech
Fri, 07/5/19 - 01:35 pm
CAR-T
Bristol-Myers Squibb
cytokine release syndrome
Draper and Bristol-Myers Squibb Ink Toxicity Testing Deal
BioSpace
Fri, 06/28/19 - 12:25 pm
Draper
Bristol-Myers Squibb
tissue models
toxicity testing
The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)
Yahoo/Motley Fool
Fri, 06/28/19 - 10:14 am
Bristol-Myers Squibb
Celgene
M&A
BeiGene
tislelizumab
Otezla
Bristol-Myers Squibb: Losing Otezla Might Be Challenging
Market Realist
Tue, 06/25/19 - 09:28 am
Bristol-Myers Squibb
Celgene
M&A
Otezla
Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market
Endpoints
Mon, 06/24/19 - 11:25 am
Bristol-Myers Squibb
Opdivo
Bayer
Nexavar
liver cancer
clinical trials
In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later
Endpoints
Mon, 06/24/19 - 11:23 am
Bristol-Myers Squibb
Opdivo
Otezla
M&A
FTC
Celgene
Abbvie proves the best at getting the most out of its workers
EP Vantage
Fri, 06/21/19 - 09:44 am
AbbVie
Bristol-Myers Squibb
Sanofi
AstraZeneca
revenue per employee
What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?
Motley Fool
Thu, 06/20/19 - 10:49 am
Bristol-Myers Squibb
Celgene
M&A
'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops
Endpoints
Wed, 06/19/19 - 10:29 am
Catalent
Europe
Bristol-Myers Squibb
Italy
gene therapy
CDMOs
Meet the Top Ten Drugs of 2024 (Maybe)
Drug Channels
Tue, 06/18/19 - 11:46 pm
AbbVie
Humira
Merck
Keytruda
Eliquis
Bristol-Myers Squibb
Imbruvica
Opdivo
Revlimid
Celgene
As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup
Endpoints
Mon, 06/17/19 - 10:06 am
BeiGene
Bristol-Myers Squibb
Celgene
Opdivo
BMS reveals its post-Celgene takeover management team
Pharmaforum
Thu, 06/6/19 - 09:30 am
Bristol-Myers Squibb
Celgene
M&A
Eli Lilly, BMS among 77 drugmakers targeted in Chinese financial probe
Fierce Pharma
Wed, 06/5/19 - 12:03 am
China
Sanofi
Eli Lilly
Bristol-Myers Squibb
In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful
Fierce Biotech
Tue, 06/4/19 - 11:02 am
Celgene
Bristol-Myers Squibb
Acceleron
luspatercept
MDS
beta thalassemia
Gilead C-suite shifts again with chief commercial officer appointment
Biopharma Dive
Wed, 05/29/19 - 10:37 pm
Gilead Sciences
Bristol-Myers Squibb

Pages